Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 5090: Efficient KO of PD1 into primary T cells using a new non-integrative lentiviral particle expressing CRISPR/Cas9 system

Pascale Bouillé, Régis Gayon, Lucille Lamouroux, Alexandra Iche, Christine Duthoit and Jean-Christophe Pages
Pascale Bouillé
VECTALYS and FLASHCELL, Toulouse, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Régis Gayon
VECTALYS, Toulouse, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucille Lamouroux
VECTALYS, Toulouse, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Iche
VECTALYS, Toulouse, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Duthoit
VECTALYS, Toulouse, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Christophe Pages
INSERM U966 Faculté de Médecine, Tours, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2017-5090 Published July 2017
  • Article
  • Info & Metrics
Loading
Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC

Abstract

Gene editing by the CRISPR system shows great promises for gene therapy. Nevertheless, it must now face a number of challenges especially for the development of safe and efficient delivery tools for in vivo, as well as ex vivo gene editing. Cas9 and sgRNA delivery, mediated either by viral vectors (AAV- or Lentivirus-derived) or transfection protocols (chemical or by electroporation) have been largely and efficiently used but they bring major drawbacks incompatible with clinical applications. Indeed, viral vectors can display uncontrolled chromosomal integrations and transfection protocols are known to induce cell toxicity and/or phenotype modifications of the target cells.. Moreover, the CRISPR technology entails a “hit-and-run” mechanism that only requires a transient expression of the nuclease complex. Therefore, achieving an efficient delivery into hard-to-transfect cells, such as T cells, remains challenging and the need for delivery tools that would allow efficient transfer on most cell types without causing any cell damages is essential for downstream therapeutic applications. Here, we present an innovative tool, named LentiFlash, allowing RNA delivery into target cells without any genomic scar. The RNA encapsidation is mediated via an RNA/protein interaction: the respective properties of the MS2 bacteriophage and the lentiviral vectors have been combined to build a non-integrative packaging system in which the wild type HIV packaging sequence is replaced by the MS2 stem-loop repeats and the MS2 coat protein is inserted into the Nucleocapsid. This new vector breaks with all existing systems, as the resulting lentiparticle is able to deliver non-viral coding or non-coding RNA, at high efficiency, into the cytoplasm of any cell type. Transduction of a large range of cells, from immortalized cells to delicate primary cells, such as T cells and hematopoietic stem cells, with LentiFlash shows an efficient, fast and transient expression of proteins and RNA, with no cell phenotype modification. In particular, LentiFlash particles were successfully used to deliver Cas9, alone or in association with an sgRNA not only targeting a reporter gene into immortalized cells, but outstandingly knocking-out the PD-1 gene into primary human T lymphocytes. This new RNA delivery system is an efficient and safe tool for the delivery of CRISPR editing machinery in most cell types without affecting cell viability and phenotype. The transient, RNA-based mechanism of LentiFlash vector, preventing the risk of integration, associated with its ability to utilize lentiviral production platforms already validated in clinical settings, make it a promising tool for CRISPR therapeutic applications. As a matter of fact, beyond gene editing efficiency, safety of delivery tools is a major concern that should be addressed to move forward with CRISPR clinical development.

Citation Format: Pascale Bouillé, Régis Gayon, Lucille Lamouroux, Alexandra Iche, Christine Duthoit, Jean-Christophe Pages. Efficient KO of PD1 into primary T cells using a new non-integrative lentiviral particle expressing CRISPR/Cas9 system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5090. doi:10.1158/1538-7445.AM2017-5090

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 77 (13 Supplement)
July 2017
Volume 77, Issue 13 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 5090: Efficient KO of PD1 into primary T cells using a new non-integrative lentiviral particle expressing CRISPR/Cas9 system
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 5090: Efficient KO of PD1 into primary T cells using a new non-integrative lentiviral particle expressing CRISPR/Cas9 system
Pascale Bouillé, Régis Gayon, Lucille Lamouroux, Alexandra Iche, Christine Duthoit and Jean-Christophe Pages
Cancer Res July 1 2017 (77) (13 Supplement) 5090; DOI: 10.1158/1538-7445.AM2017-5090

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 5090: Efficient KO of PD1 into primary T cells using a new non-integrative lentiviral particle expressing CRISPR/Cas9 system
Pascale Bouillé, Régis Gayon, Lucille Lamouroux, Alexandra Iche, Christine Duthoit and Jean-Christophe Pages
Cancer Res July 1 2017 (77) (13 Supplement) 5090; DOI: 10.1158/1538-7445.AM2017-5090
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Gene- and Vector-Based Therapy

  • Abstract 5098: NG-348: a novel oncolytic virus designed to mediate anti-tumour activity via the potent and selective polyclonal activation of tumor-infiltrating T-cells
  • Abstract 5094: Precision therapeutic targeting of oncogenic FGFR3 fusions using CRISPR-Cas9 genome-editing in urothelial cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement